RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration ("FDA") has denied its most recent application seeking Breakthrough Therapy designation ("BTD") for aviptadil.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | +12.74% | +16.45% | -23.04% |
Apr. 18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
Apr. 18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.04% | 32.72M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- NRXP Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil